Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
暂无分享，去创建一个
A. Oza | J. Ledermann | T. Park-Simon | M. Friedlander | I. Vergote | S. Pignata | A. Floquet | G. Sonke | A. Poveda | T. Huzarski | R. Penson | E. Pujade-Lauraine | R. Asher | J. Korach | A. Lisyanskaya | E. A. Filho | P. Rowe | Jae Hoon Kim | Alessandra Baldoni